In Depth 1 Aug 2024
CureVac: From a failed drug to a €1.45 billion deal
In 2021, CureVac’s COVID-19 candidate came short. Discover how the company leveraged its deal with GSK to restructure and turn things around.
Curevac
- Latest Posts
Best in Biotech 7 Nov 2023
Eight biotech companies tackling infectious diseases head-on
Infectious diseases are diseases that are caused by pathogens that enter the body, hijack the body’s immune system and multiply, causing an infection. Five of the deadliest infectious diseases are measles, tuberculosis, malaria, diarrhoeal disease and influenza, according to the World Economic Forum. While Our World in Data statistics suggest that there has been almost […]
In Depth 10 Jul 2023
Unleashing the potential: Optimizing mRNA for the discovery of transformative medicines
By Dr. Alexander Zehnder, CEO, CureVac The success of mRNA vaccines in COVID-19 propelled the role of this new modality to the forefront of medicine. Not only are new prophylactic mRNA vaccines for various respiratory diseases advancing through clinical development, but mRNA medicines are now being developed in many wide-ranging applications, including cancer and rare […]
Opinion 26 Apr 2023
Can mRNA vaccines tackle multiple diseases?
By Dr. Myriam Mendila, chief development officer of CureVac World Immunization Week is April 24-30, and it’s an important week to highlight the action needed and to promote the use of vaccines to protect people around the world, of all ages, against infectious diseases. World Immunization Week aims to promote the use of vaccines to […]
In Depth 4 Jul 2022
The COVID-19 pandemic has driven RNA therapeutics into the mainstream
As messenger RNA vaccines save lives around the world, and RNA interference drugs are greenlit for rare diseases, the field of RNA therapeutics is now moving faster than ever before. The COVID-19 pandemic proved a turning point for the biotech companies BioNTech and Moderna, which specialize in developing technology based on messenger RNA (mRNA). The […]
News and Trends 15 Feb 2022
Next-Gen Covid-19 Vaccines and Drugs Crowd into Late-Stage Trials
Despite the widespread rollout of vaccines over 2021, the Covid-19 pandemic remains a threat to healthcare systems worldwide. Numerous treatments and vaccines are hitting the late-stage pipeline, which could greatly expand the anti-Covid-19 arsenal. Two years ago, the Covid-19 pandemic swept the world and left economic disruption, healthcare crises, and widespread lockdowns in its wake. […]
ADVERTISEMENT
ADVERTISEMENT
Best in Biotech 20 Dec 2021
The Billion-Euro European Biotech Companies in 2022
Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European biotech is growing steadily and this year we welcome a few new names to the list of billion-euro biotechs. However, we also had to say goodbye to some of them, including Cellectis, Autolus, and Orchard […]
Best in Biotech 11 Jan 2021
The 21 European Biotech Companies To Watch in 2021
As we enter 2021, the biotech industry is already bustling with activity. Here’s a list of 21 European biotech companies likely to make a big splash in the biotechnology sector over the next year. There were many memorable moments for the European biotech industry in 2020. The Covid-19 pandemic took over the media and many […]
Best in Biotech 28 Dec 2020
A Year to Remember: The Biggest European Biotech News in 2020
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. After the many drug approvals, startup foundations, and venture capital highs we saw in 2019, it looked like 2020 was going to be a comfortable […]
News and Trends 17 Aug 2020
CureVac Continues Covid-19 Vaccine Funding Frenzy with €180M IPO
The share price of CureVac has skyrocketed almost fivefold after the Covid-19 vaccine developer priced a Nasdaq IPO at €180M ($213M). The excitement around messenger RNA (mRNA) vaccines against Covid-19 could also benefit other players in mRNA therapeutics. CureVac’s IPO was priced at €14 ($16) per share, giving the German company a valuation of around […]
News and Trends 23 Jul 2020
Pharma Giant GSK and mRNA Biotech CureVac Ink €1B Deal
GlaxoSmithKline (GSK) has struck a deal worth up to €1B with the German biotechnology company CureVac to co-develop messenger RNA drugs for infectious diseases. Under the terms of the deal, GSK will fund the development and manufacturing of up to five mRNA-based vaccines and antibody drugs targeting undisclosed infectious diseases. CureVac’s current rabies and Covid-19 […]
News and Trends 17 Jun 2020
German Government Invests €300M in mRNA Biotech CureVac
The Federal Republic of Germany will invest €300M in CureVac, the homegrown biotech that is developing a vaccine for Covid-19 using messenger RNA technology. The unusually large investment will be made through the state-owned bank Kreditanstalt für Wiederaufbau, which will gain a 23% stake in the company. “CureVac retains complete operational and strategic independence,” Franz-Werner […]
ADVERTISEMENT